Safety Study of SGN-CD70A in Cancer Patients

Inclusion Criteria: * Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma * Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies * Confirmed positive CD70 expression on tumor tissue * Eastern Cooperative Oncology Group performance status 0 or 1 * Adequate baseline hematologic, pulmonary, renal, and hepatic function * Measurable disease Exclusion Criteria: * Prior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatment * Patients \<100 days since prior allogeneic stem cell transplant * Less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment